Barclays PLC Has $519,000 Position in Accolade, Inc. (NASDAQ:ACCD)

Barclays PLC lifted its holdings in shares of Accolade, Inc. (NASDAQ:ACCD) by 8.3% during the fourth quarter, HoldingsChannel reports. The firm owned 151,493 shares of the company’s stock after acquiring an additional 11,592 shares during the quarter. Barclays PLC’s holdings in Accolade were worth $519,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Fairman Group LLC increased its position in shares of Accolade by 58.5% during the fourth quarter. Fairman Group LLC now owns 1,802,399 shares of the company’s stock worth $6,164,000 after acquiring an additional 665,112 shares in the last quarter. Whetstone Capital Advisors LLC boosted its holdings in Accolade by 58.9% during the fourth quarter. Whetstone Capital Advisors LLC now owns 1,585,643 shares of the company’s stock worth $5,423,000 after purchasing an additional 587,754 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in shares of Accolade by 40.9% in the 4th quarter. Kennedy Capital Management LLC now owns 1,065,757 shares of the company’s stock valued at $3,645,000 after acquiring an additional 309,201 shares in the last quarter. Tocqueville Asset Management L.P. raised its holdings in Accolade by 100.0% during the fourth quarter. Tocqueville Asset Management L.P. now owns 580,000 shares of the company’s stock worth $1,984,000 after acquiring an additional 290,000 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Accolade by 84.1% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 634,470 shares of the company’s stock worth $2,170,000 after purchasing an additional 289,747 shares during the last quarter. 84.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Raymond James reissued a “market perform” rating on shares of Accolade in a research note on Thursday, January 9th. Stephens reaffirmed an “equal weight” rating and issued a $7.03 price objective on shares of Accolade in a research report on Wednesday, February 12th. Truist Financial lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th. Piper Sandler lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $7.03 target price (down from $8.00) on shares of Accolade in a report on Thursday, January 9th. Thirteen research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.51.

Accolade Price Performance

Shares of ACCD stock opened at $7.02 on Friday. The business has a fifty day simple moving average of $7.00 and a 200 day simple moving average of $5.62. The company has a market cap of $575.59 million, a P/E ratio of -3.12 and a beta of 2.10. The company has a quick ratio of 2.63, a current ratio of 2.63 and a debt-to-equity ratio of 0.67. Accolade, Inc. has a twelve month low of $3.08 and a twelve month high of $8.05.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.